ALNY ALNYLAM PHARMACEUTICALS, INC. Insider Trading

Director David E I Pyott sells 3,830 shares at avg $299.18 under pre-arranged 10b5-1 plan; retains 1,582 shares post-transaction.

Director David E I Pyott executed 5 separate sales totaling 3,830 shares for $1,145,852.75 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-12, reducing his non-derivative holdings by 70.8% from 5,412 shares to 1,582 shares. The sales were executed at prices ranging from $297.71 to $302.65, yielding a blended average price of $299.18, against a current market price of $292.58. Because this transaction is governed by a scheduled 10b5-1 plan rather than discretionary choice, the filing reflects automatic execution rather than a market-timing decision by the insider. The company's fundamentals show strong growth (annual revenue growth of 65.2%, net income of $251.1M on $1.2B quarterly revenue) and a market cap of $38.8B, though the stock is currently -41.0% from its 52-week high of $495.55. His prior sales at ALNY show mixed timing outcomes (the most recent sale on 2025-03-24 saw a 30-day decline of -19.1%), though this specific filing represents scheduled divestiture rather than discretionary positioning.

CHRO Melissa McLaughlin sells 2,286 shares for $755,328.85 via 10b5-1 plan on April 6, 2026

Melissa McLaughlin, Chief Human Resources Officer of Alnylam Pharmaceuticals, executed 5 separate sales totaling 2,286 shares for $755,328.85 on April 6, 2026, reducing her holdings from 11,729 shares to 9,443 shares. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on December 16, 2025, indicating this was a scheduled, non-discretionary sale rather than a response to current market conditions. The sales occurred across multiple price points ranging from $320.14 to $333.94 per share with a blended average price of $330.42, and Ms. McLaughlin retains 9,443 shares post-transaction, maintaining material exposure to the company.

CSO Kevin Joseph Fitzgerald sold 1,652 shares for $528,189.23 on 2026-03-03 per pre-arranged 10b5-1 plan.

Kevin Joseph Fitzgerald, CSO & EVP Head of Research at Alnylam Pharmaceuticals, executed 4 separate sales totaling 1,652 shares for $528,189.23 on 2026-03-03 at prices ranging from $316.55 to $321.58, with a blended average price of $319.73. This transaction reduces his post-transaction holdings to 21,860 shares from a pre-transaction level of 23,512 shares, representing a -7.0% reduction in his position. The FLAG indicates this sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning the transaction was scheduled and non-discretionary rather than a reflection of current market judgment. As a scheduled disposition under Rule 10b5-1, this filing provides no signal regarding insider conviction or market outlook at the time of execution.

EVP Chief R&D Garg sells 4,627 shares for $1.5M via 10b5-1 plan

Pushkal Garg (EVP Chief R&D) executed 5 separate sales totaling 4,627 shares for $1,533,099.58 on 2026-02-27 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-20. The sales reduced his holdings from 26,756 shares to 22,129 shares, a 17.3% reduction. Since the transaction is governed by a scheduled trading plan, it reflects a predetermined execution schedule rather than a discretionary response to current market conditions. The blended average sale price was $331.34 across the five transactions.

CSO Kevin Fitzgerald sold 2,041 shares of ALNY at $331.96 under pre-arranged 10b5-1 plan

Kevin Fitzgerald, CSO & EVP of Research at Alnylam Pharmaceuticals, sold 2,041 shares on 2026-02-17 for a total value of $677,531.58, reducing his holdings from 23,305 shares to 21,264 shares. This transaction was executed under a 10b5-1 trading plan adopted on 2025-08-14, meaning the sale was scheduled in advance rather than discretionary. Because the trade follows a pre-arranged plan, it reflects no particular timing judgment or conviction signal from the insider. The 8.8% reduction in holdings represents a modest position adjustment within the context of a scheduled trading program.

CSO & EVP Kevin Joseph Fitzgerald sold 2,290 shares for $848,064.62 via pre-arranged 10b5-1 plan on 2026-01-13

Fitzgerald executed 6 separate sales totaling 2,290 shares for $848,064.62 on 2026-01-13, with prices ranging from $367.52 to $374.33 and a blended average price of $370.33. This represents a -9.7% reduction from his pre-transaction holdings of 23,554 shares, leaving him with 21,264 shares post-transaction. The sale was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning it was scheduled rather than discretionary. As a CSO and EVP with research oversight responsibilities, this scheduled disposition reflects execution of a pre-planned program rather than a fresh market signal about near-term company prospects.

ALNY CSO Kevin Fitzgerald sold 12,128 shares for $5.5M (avg $452.18) via scheduled 10b5-1 plan adopted 2025-08-14.

Kevin Fitzgerald, CSO and EVP of Head of Research at Alnylam Pharmaceuticals, executed 11 separate sales totaling 12,128 shares for $5,483,989.61 at prices ranging from $449.00 to $463.08 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning the sale was scheduled in advance rather than discretionary. The sale reduced his holdings by 36.3%, from 33,392 shares to 21,264 shares post-transaction. As a scheduled trade under a 10b5-1 plan, this represents routine portfolio execution rather than a signal reflecting current conviction about the company's prospects or market conditions.

CEO Yvonne Greenstreet sold 25,650 shares for $11.6M via scheduled 10b5-1 plan (Nov 12-13)

Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals, executed 20 separate sales over November 12–13, 2025, totaling 25,650 shares for $11,613,003.42 at a blended average price of $452.75. This sale reduces her holdings from 91,059 shares to 65,409 shares, a 28.2% reduction in stake. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, meaning these sales were scheduled and not discretionary. The large dollar volume and multi-day execution pattern reflect a structured liquidation, typical of Rule 10b5-1 programs designed to execute predetermined reductions over time rather than spot decisions.

EVP Pushkal Garg sells 3,022 shares for $1,364,387.18 under pre-arranged 10b5-1 plan; holds 20,221 shares post-transaction

Pushkal Garg, EVP Chief R&D at Alnylam Pharmaceuticals, executed 5 separate sales on 2025-10-03 totaling 3,022 shares for $1,364,387.18 at an average price of $451.48 per share. This transaction reduces his holdings by 13.0% from 23,243 shares to 20,221 shares. However, this sale is part of a pre-arranged 10b5-1 trading plan adopted on 2024-09-11, meaning the execution was scheduled rather than discretionary. The pre-arranged nature of the plan precludes timing-based interpretation of this particular sale.

Director Colleen F Reitan sold 18,000 shares of ALNY for $8,416,729.64 via scheduled 10b5-1 plan

Director Colleen F Reitan executed 16 separate sales totaling 18,000 shares for $8,416,729.64 on 2025-09-09, reducing her holdings from 18,775 shares to 775 shares (a 95.9% reduction). The sales were executed across a range of prices from $457.44 to $480.98 with a blended average price of $467.60, consistent with a systematic multi-lot liquidation. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-06-10, meaning the sales were scheduled rather than discretionary. The near-complete exit from a material director position warrants investor attention regarding her views on the company's outlook, though the pre-planned nature of the trades constrains inference about real-time decision-making.